Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer

Li, Weihao; Zhou, Chi; Yu, Long; Hou, Zhenlin; Liu, Huashan; Kong, Ling-Heng; Xu, Yanbo; He, Jiahua; Jin, Lan; Ou, Qingjian; Fang, Yujing; Lu, Zhenhai; Wu, Xiaojun; Pan, Zhizhong; Peng, Jianhong; Lin, Junzhong

doi:10.1080/15548627.2023.2249762

Public

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer

Published in Autophagy • Aug 24, 2023

Authors:

Weihao Li

Chi Zhou

Long Yu

Abstract

Bevacizumab plays an important role in the first and second line treatment for metastatic colorectal cancer (CRC). And induction of hypoxia and the tumors response to it plays an important role in determining the efficacy of antiangiogenic therapy while the connection between them remains unclear. H...

Subject

Biology

Cancer research

Bevacizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!